What is RedShiftBio?
RedShiftBio is a specialized provider of advanced analytical instrumentation, primarily serving the research, development, and manufacturing sectors of the protein therapeutics industry. At the core of its value proposition is the patented Microfluidic Modulation Spectroscopy (MMS) technology. This breakthrough platform enables the direct, automated probing of the biophysical structure of proteins, providing comprehensive secondary structure data across five key measurements in a single workflow. By replacing the traditional, fragmented approach of utilizing multiple instruments, RedShiftBio significantly enhances laboratory efficiency and data accuracy for drug developers. The company occupies a vital niche in the life sciences market, bridging the gap between complex protein characterization and the rapid, high-throughput requirements of modern pharmaceutical manufacturing.
How much funding has RedShiftBio raised?
RedShiftBio has raised a total of $71.7M across 9 funding rounds:
Series B
$6.2M
Private Equity
$2.4M
Private Equity
$751K
Private Equity
$1M
Series C
$11M
Series D
$18M
Debt
$350K
Series E
$20M
Series B (2008): $6.2M led by Emerson Ventures, Alta California Partners, Technology Venture Partners, and InterWest Partners
Private Equity (2012): $2.4M, investors not publicly disclosed
Private Equity (2014): $751K featuring Technology Venture Partners, LLC
Private Equity (2015): $998K, investors not publicly disclosed
Series C (2017): $11M with participation from Technology Venture Partners and Waters
Series D (2020): $18M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Series E (2021): $20M featuring Illumina Ventures, Technology Venture Partners, and Waters
Key Investors in RedShiftBio
Illumina Ventures
A leader in genomics and precision health investing, focused on building an ecosystem that translates investment into innovation to enhance human health.
Technology Venture Partners
A growth-equity firm dedicated to accelerating high-potential technology companies through strategic insight and over 50 years of collective venture-investing experience.
Waters
A global leader in analytical software and instrumentation, committed to solving complex scientific problems to improve human health and well-being.
What's next for RedShiftBio?
With the recent influx of capital, RedShiftBio is well-positioned to accelerate its market penetration and further refine its MMS technology platform. The strategic involvement of industry leaders suggests a focus on deepening integration within genomics and precision health workflows. Future growth will likely center on expanding the application of its instrumentation to address emerging challenges in biologics, such as stability testing and formulation development. As the company continues to scale, it will likely prioritize the enhancement of its automated analysis capabilities, ensuring that its technology remains the gold standard for biophysical characterization in an increasingly competitive global landscape.
See full RedShiftBio company page
